PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
21504648-10	2011	EIA confirmed that PGE2 production increased by 4.8-fold in strips of detrusor free of urothelium after 15 minutes of incubation and that this production was blocked by ibuprofen and a COX-1 inhibitor.	Dinoprostone	19-23	cytochrome c oxidase subunit I	Oryctolagus cuniculus	185-190
23263814-8	2012	The results demonstrated that diacetylated obovatol has antiplatelet activities through inhibition of COX-1 and LOX activities.	obovatol	43-51	cytochrome c oxidase subunit I	Oryctolagus cuniculus	102-107
23132562-6	2012	On the other hand, it significantly inhibited the formation of arachidonic acid metabolites, including thromboxane A(2) (TXA(2)), prostaglandin D(2), and 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE), by suppression of cyclooxygenase (COX)-1 and lipoxygenase (LOX) activities.	Arachidonic Acid	63-79	cytochrome c oxidase subunit I	Oryctolagus cuniculus	226-248
19573602-9	2010	Diabetes enhances the vasodilator response of the rabbit carotid artery to testosterone by a mechanism that at least includes an increased modulatory activity of the endothelial nitric oxide and an augmented release of COX-2 vasodilator, prostacyclin rather than the absence of COX-1 vasoconstrictor, thromboxane A(2).	Testosterone	75-87	cytochrome c oxidase subunit I	Oryctolagus cuniculus	278-283
21351868-10	2011	Aqueous and ICB ketorolac concentrations exceeded its IC(50) for COX-1 and COX-2 at peak and trough.	Ketorolac	16-25	cytochrome c oxidase subunit I	Oryctolagus cuniculus	65-70
21351868-14	2011	The difference in inflammation suppression may be due to differences in tissue concentrations and/or greater COX-1 suppression by ketorolac 0.45%.	Ketorolac	130-139	cytochrome c oxidase subunit I	Oryctolagus cuniculus	109-114
21080066-8	2011	Interestingly, Estradiol respectively increased and decreased the expression of Cyclooxygenase (COX)-1 and COX-2, to a significant extent.	Estradiol	15-24	cytochrome c oxidase subunit I	Oryctolagus cuniculus	80-102
20513575-14	2010	Because ibuprofen inhibits both COX-1 and COX-2, whereas rofecoxib only inhibits COX-2, ibuprofen therapy appears to offer a greater beneficial effect on tendon repair by reducing formation of adhesions.	Ibuprofen	8-17	cytochrome c oxidase subunit I	Oryctolagus cuniculus	32-37
19361808-3	2010	We have examined whether gene transfer-mediated overexpression of COX-1 in grafted veins (1) increases PGI(2) and cyclic AMP (cAMP) production, (2) leads to vasodilation and improved local blood flow in the presence of hypercholesterolemia, and (3) reduces neointima formation.	Prostaglandins I	103-106	cytochrome c oxidase subunit I	Oryctolagus cuniculus	66-71
19361808-3	2010	We have examined whether gene transfer-mediated overexpression of COX-1 in grafted veins (1) increases PGI(2) and cyclic AMP (cAMP) production, (2) leads to vasodilation and improved local blood flow in the presence of hypercholesterolemia, and (3) reduces neointima formation.	Cyclic AMP	114-124	cytochrome c oxidase subunit I	Oryctolagus cuniculus	66-71
19361808-3	2010	We have examined whether gene transfer-mediated overexpression of COX-1 in grafted veins (1) increases PGI(2) and cyclic AMP (cAMP) production, (2) leads to vasodilation and improved local blood flow in the presence of hypercholesterolemia, and (3) reduces neointima formation.	Cyclic AMP	126-130	cytochrome c oxidase subunit I	Oryctolagus cuniculus	66-71
18759857-5	2009	However, at 10(-4) mol/L, DFU augmented histamine-stimulated aminopyrine uptake by 135% and inhibited PGE(2) synthesis by 39%, indicating an inhibition of COX-1 at this higher concentration.	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone	26-29	cytochrome c oxidase subunit I	Oryctolagus cuniculus	155-160
17267581-10	2007	These results suggest that 5,6-EET-induced contraction is primarily dependent on COX-1 activity.	5,6-epoxy-8,11,14-eicosatrienoic acid	27-34	cytochrome c oxidase subunit I	Oryctolagus cuniculus	81-86
21063331-7	2008	This study revealed that COX-1 expression should be a pharmacological target following TBI, and COX-2 should also be evaluated in this aspect, and indomethacin is more effective than nimodipine for blocking COX-1.	Indomethacin	147-159	cytochrome c oxidase subunit I	Oryctolagus cuniculus	207-212
21063331-7	2008	This study revealed that COX-1 expression should be a pharmacological target following TBI, and COX-2 should also be evaluated in this aspect, and indomethacin is more effective than nimodipine for blocking COX-1.	Nimodipine	183-193	cytochrome c oxidase subunit I	Oryctolagus cuniculus	207-212
17267581-0	2007	Cyclooxygenase (COX)-1 and COX-2 participate in 5,6-epoxyeicosatrienoic acid-induced contraction of rabbit intralobar pulmonary arteries.	5,6-epoxy-8,11,14-eicosatrienoic acid	48-76	cytochrome c oxidase subunit I	Oryctolagus cuniculus	0-22
16920097-1	2006	Licofelone is an analogue of arachidonic acid that inhibits 5-lipoxygenase (LOX), cyclooxygenase (COX)-1 and COX-2.	licofelone	0-10	cytochrome c oxidase subunit I	Oryctolagus cuniculus	82-104
17267581-7	2007	Differential metabolism of 5,6-EET by COX-1 and COX-2 does not explain the primary dependence of PA contraction on COX-1 activity because 5,6-EET was metabolized similarly by both COX isoforms.	5,6-epoxy-8,11,14-eicosatrienoic acid	27-34	cytochrome c oxidase subunit I	Oryctolagus cuniculus	38-43
16920097-1	2006	Licofelone is an analogue of arachidonic acid that inhibits 5-lipoxygenase (LOX), cyclooxygenase (COX)-1 and COX-2.	Arachidonic Acid	29-45	cytochrome c oxidase subunit I	Oryctolagus cuniculus	82-104
15931878-13	2005	CO I and CO II, or CO II, is better than CO I.	co ii	19-24	cytochrome c oxidase subunit I	Oryctolagus cuniculus	9-13
16846546-8	2006	RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).	Ketorolac	9-18	cytochrome c oxidase subunit I	Oryctolagus cuniculus	53-58
16846546-8	2006	RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).	Ketorolac	9-18	cytochrome c oxidase subunit I	Oryctolagus cuniculus	215-220
16846546-11	2006	CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1.	Ketorolac	13-22	cytochrome c oxidase subunit I	Oryctolagus cuniculus	37-42
16846546-11	2006	CONCLUSIONS: Ketorolac is relatively COX-1 selective while bromfenac is potently selective for COX-2 over COX-1.	bromfenac	59-68	cytochrome c oxidase subunit I	Oryctolagus cuniculus	106-111
15627832-10	2004	Less than 3-fold changes in mRNA levels for COX-1 and COX-2 in the iris-ciliary body were noted after PGE2, FR122047, FR188582, diclofenac sodium or dexamethasone phosphate disodium treatment.	Dinoprostone	102-106	cytochrome c oxidase subunit I	Oryctolagus cuniculus	44-49
15627832-10	2004	Less than 3-fold changes in mRNA levels for COX-1 and COX-2 in the iris-ciliary body were noted after PGE2, FR122047, FR188582, diclofenac sodium or dexamethasone phosphate disodium treatment.	Diclofenac	128-145	cytochrome c oxidase subunit I	Oryctolagus cuniculus	44-49
15627832-10	2004	Less than 3-fold changes in mRNA levels for COX-1 and COX-2 in the iris-ciliary body were noted after PGE2, FR122047, FR188582, diclofenac sodium or dexamethasone phosphate disodium treatment.	dexamethasone 21-phosphate	149-172	cytochrome c oxidase subunit I	Oryctolagus cuniculus	44-49
15627832-10	2004	Less than 3-fold changes in mRNA levels for COX-1 and COX-2 in the iris-ciliary body were noted after PGE2, FR122047, FR188582, diclofenac sodium or dexamethasone phosphate disodium treatment.	Edetic Acid	173-181	cytochrome c oxidase subunit I	Oryctolagus cuniculus	44-49
15627832-11	2004	CONCLUSION: It is possible that enzyme activities of both COX-1 and COX-2 may be involved in the mechanism of PGE2-induced aqueous flare elevation in pigmented rabbits.	Dinoprostone	110-114	cytochrome c oxidase subunit I	Oryctolagus cuniculus	58-63
15086459-0	2004	Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney.	Prostaglandins E	20-23	cytochrome c oxidase subunit I	Oryctolagus cuniculus	70-75
15086459-12	2004	CONCLUSION: Together, these studies suggest mPGES-1 colocalizes with both COX-1 and COX-2 to mediate the biosynthesis of PGE2 in the kidney.	Dinoprostone	121-125	cytochrome c oxidase subunit I	Oryctolagus cuniculus	74-79
12061021-2	2002	AIM: This study was aimed to evaluate the effect of drugs inhibiting both cyclooxygenase (COX) isoforms COX-1 and COX-2 on vasoconstrictor responses to noradrenaline in the rabbit renal artery and to compare these responses with femoral artery as a systemic vessel.	Norepinephrine	152-165	cytochrome c oxidase subunit I	Oryctolagus cuniculus	104-109
12772774-4	2003	RESULTS: Prostaglandins are derived from COX-1 activity in the normal esophagus.	Prostaglandins	9-23	cytochrome c oxidase subunit I	Oryctolagus cuniculus	41-46
14736236-3	2004	Celecoxib (Celebrex), valdecoxib (Bextra), and rofecoxib (Vioxx) are nonsteroidal antiinflammatory drugs (NSAIDs) due to selective inhibition of inducible cyclooxygenase COX-2 while sparing inhibition of constitutive COX-1.	Celecoxib	0-9	cytochrome c oxidase subunit I	Oryctolagus cuniculus	217-222
14736236-3	2004	Celecoxib (Celebrex), valdecoxib (Bextra), and rofecoxib (Vioxx) are nonsteroidal antiinflammatory drugs (NSAIDs) due to selective inhibition of inducible cyclooxygenase COX-2 while sparing inhibition of constitutive COX-1.	valdecoxib	22-32	cytochrome c oxidase subunit I	Oryctolagus cuniculus	217-222
14736236-3	2004	Celecoxib (Celebrex), valdecoxib (Bextra), and rofecoxib (Vioxx) are nonsteroidal antiinflammatory drugs (NSAIDs) due to selective inhibition of inducible cyclooxygenase COX-2 while sparing inhibition of constitutive COX-1.	rofecoxib	47-56	cytochrome c oxidase subunit I	Oryctolagus cuniculus	217-222
12077551-3	2002	In the fully embryonic cortical zone immunohistochemical expression of COX 1 is seen in all cells of the CD ampulla, while COX 2 is lacking within the nephron inducer.	Cadmium	105-107	cytochrome c oxidase subunit I	Oryctolagus cuniculus	71-76
12077551-5	2002	In contrast, a heterogeneous expression profile for COX 1 and 2 is found in the outer medullary CD (OMCD), since not all cells showed immunohistochemical labeling.	Cadmium	96-98	cytochrome c oxidase subunit I	Oryctolagus cuniculus	52-63
9249588-1	1997	Prostaglandin synthesis requires cyclooxygenase-1 (COX1) or -2 (COX2), which mediate the conversion of arachidonate to prostaglandin H2.	Prostaglandins	0-13	cytochrome c oxidase subunit I	Oryctolagus cuniculus	51-55
9249588-1	1997	Prostaglandin synthesis requires cyclooxygenase-1 (COX1) or -2 (COX2), which mediate the conversion of arachidonate to prostaglandin H2.	Arachidonic Acid	103-115	cytochrome c oxidase subunit I	Oryctolagus cuniculus	51-55
9249588-1	1997	Prostaglandin synthesis requires cyclooxygenase-1 (COX1) or -2 (COX2), which mediate the conversion of arachidonate to prostaglandin H2.	Prostaglandin H2	119-135	cytochrome c oxidase subunit I	Oryctolagus cuniculus	51-55
11472739-3	2001	COX-1 was detected as the major isoform by immunoblot analysis in extracts from aortas of normal and 8 week cholesterol-fed animals with COX-2 being induced in atherosclerotic plaques from cholesterol-fed animals.	Cholesterol	108-119	cytochrome c oxidase subunit I	Oryctolagus cuniculus	0-5
11472739-3	2001	COX-1 was detected as the major isoform by immunoblot analysis in extracts from aortas of normal and 8 week cholesterol-fed animals with COX-2 being induced in atherosclerotic plaques from cholesterol-fed animals.	Cholesterol	189-200	cytochrome c oxidase subunit I	Oryctolagus cuniculus	0-5
11247918-5	2001	In addition, the level of PGE2 augmented by IL-1alpha was due to the increase of cyclooxygenase (COX) activity, which was inhibited by progesterone and 17beta-estradiol as well as by indomethacin and a specific COX-2 inhibitor, NS-398, but not by the well-known COX-1 inhibitor, aspirin.	Dinoprostone	26-30	cytochrome c oxidase subunit I	Oryctolagus cuniculus	262-267
10964725-2	2000	Acetylsalycilic acid, nimesulide, or SQ22536 was used as respective antagonist of COX-1, COX-2, or adenylate cyclase using aortic rings precontracted with phenylephrine and exposed to cumulative concentrations of acetylcholine (ACh).	Aspirin	0-20	cytochrome c oxidase subunit I	Oryctolagus cuniculus	82-87
10964725-2	2000	Acetylsalycilic acid, nimesulide, or SQ22536 was used as respective antagonist of COX-1, COX-2, or adenylate cyclase using aortic rings precontracted with phenylephrine and exposed to cumulative concentrations of acetylcholine (ACh).	nimesulide	22-32	cytochrome c oxidase subunit I	Oryctolagus cuniculus	82-87
10964725-2	2000	Acetylsalycilic acid, nimesulide, or SQ22536 was used as respective antagonist of COX-1, COX-2, or adenylate cyclase using aortic rings precontracted with phenylephrine and exposed to cumulative concentrations of acetylcholine (ACh).	9-(tetrahydro-2-furyl)-adenine	37-44	cytochrome c oxidase subunit I	Oryctolagus cuniculus	82-87
10850857-4	2000	In contrast to diclofenac (IC50 = 0.12 microM), nepafenac exhibited only weak COX-1 inhibitory activity (IC50 = 64.3 microM).	nepafenac	48-57	cytochrome c oxidase subunit I	Oryctolagus cuniculus	78-83
10850857-5	2000	However, amfenac was a potent inhibitor of both COX-1 (IC50 = 0.25 microM) and COX-2 activity (IC50 = 0.15 microM).	Amfenac	9-16	cytochrome c oxidase subunit I	Oryctolagus cuniculus	48-53